Orphan Drug List. Drug Name Dosage Form Route of Admin ATC Code Description List Name. Amyl Nitrite INHALER INHALATION V۰۳AB

Rayos Prior Authorization Program Summary

Rayos Prior Authorization Program Summary FDA APPROVED INDICATIONS AND DOSAGE FDA-Approved Indications: 1 Agent Indication Dosage Rayos (prednisone delayedrelease tablet) as an anti-inflammatory or immunosuppressive

New Mexico Health Connections Drug Safety Updates. Drug Safety Updates Q Route of Administration. Action. Brand Name Generic Name Indications

Q4 2017 Advair Diskus salmeterol Asthma, COPD inhaler Advair HFA salmeterol Asthma inhaler Airduo Respiclick salmeterol Asthma inhaler Alecensa alectinib Non-Small Cell Lung Cancer Genentech announced

Manufacturing and Marketing permission issued from SND Division from to

Manufacturing and Marketing permission issued from SND Division from 01.01.2018 to 31.05.2018. S.No Drug Name Composition Indication Date of Approval As a component of multi agent Pegaspargase Each vial

Immunodeficiencies HIV/AIDS

Immunodeficiencies HIV/AIDS Immunodeficiencies Due to impaired function of one or more components of the immune or inflammatory responses. Problem may be with: B cells T cells phagocytes or complement

ATC/DDD Classification

(Temporary) The following anatomical therapeutic codes (ATC), defined daily doses (DDD) and alterations were considered by the WHO International Working Group for Drug Statistics Methodology at its meeting

Manufacturing and Marketing permission issued from SND Division from to

Manufacturing and Marketing permission issued from SND Division from 01.01.2017 to 17.07.2017. S.No. Drug Name Indication Date of Approval 1 Sofosbuvir 400 film coated Tablet In combination with other

Clinical Trial List

Clinical Trial List 2005 2008 Service Driven. Quality Focused. Global Perspective. Clinical Trial List 2005-2008 1 Pharmacokinetic A Two-Period, Single Dose Pharmacokinetic Study of Three Sustained-Release

ΟΡΦΑΝΑ ΦΑΡΜΑΚΑ (κατά FDA) ΠΟΥ ΕΙΣΑΓΟΝΤΑΙ ΑΠΟ ΤΟ ΙΦΕΤ

ΟΡΦΑΝΑ ΦΑΡΜΑΚΑ (κατά FDA) ΠΟΥ ΕΙΣΑΓΟΝΤΑΙ ΑΠΟ ΤΟ ΙΦΕΤ FDA APPROVAL [ταξινόμηση κατά δραστική ουσία (generic name)] Generic Name Trade Name Orphan Designation: Approved Orphan Indication: SPONSOR ΔΙΑΘΕΣΗ

١ !" # +& )* $ ) # ' & "( %&. ) #, )+ " & $ # $,# 10 (SARS) )% *% % '. &' ( % $ # ". # * +,.( ' )% *% % ' / 4 % /$ %& (. )% *% % %. MERS % SARS).. 1391 2 1391. ۴ ۵ SARS . 10 ۶ ٧ ٢۴ ٢۴ September September

Manufacturing and Marketing permission issued from SND Division from to

Manufacturing and Marketing permission issued from SND Division from 01.01.2018 to 04.07.2018. S.No Drug Name Composition Indication Date of Approval As a component of multi agent Pegaspargase Each vial

Uses Location(s) Par Levels a Location(s) Par Levels. Min: 18 Max: 36. Min: 22 Max: 33. Talyst (Refrig) Talyst (Refrig) Min: 2 b Talyst (Refrig)

U N C M E D I C A L C E N T E R G U I D E Antidotes Used in Poisonings and Ingestions The purpose of this guide is to describe the locations and quantities of antidotes to be maintained at UNC Medical

OTC DRUGS' LIST. No Drug Name Dosage Form Route of Admin ATC Code Description Date

فهرست داروهاي OTC OTC DRUGS' LIST تاريخ توضيحات دسته دارو راه مصرف شكل دارويي نام دارو رديف No Drug Name Dosage Form Route of Admin ATC Code Description Date ١ ٢ ٣ ۴ ۵ ۶ ٧ ٨ ٩ ١٠ ١١ ١٢ ١٣ ١۴ A.C.A* TABLET

POISON ANTIDOTE DOSE* COMMENTS

Antidotes Acetaminophen N-acetylcysteine 140 mg/kg initial oral dose, followed Most effective within 16 24 hr; may by 70 mg/kg every 4 hr 17 doses be useful after chronic intoxication or intravenously

Update in Poison Management. Update in Poison Management. Antidote Use. Fomepizole. Pediatric Ingestions 1. No financial disclosures

Update in Poison Management No financial disclosures Robert J. Hoffman, MD,MS FACMT, FACEP, FAAEM, FAAP Department of Emergency Medicine Albert Einstein College of Medicine New York, New York Update in

Area Drug and Therapeutics Committee Prescribing Supplement No 30 April 2009

Area Drug and Therapeutics Committee Prescribing Supplement No 30 In this issue Drugs currently being considered by SMC advice due on 11 May 2009 Drug Safety Update (MHRA) New updated wound management

ATC/DDD classification

The Anatomical Therapeutic Chemical (ATC) classification system and the Defined Daily Dose (DDD) as a measuring unit are tools for exchanging and comparing data on drug use at international, national or

Chapter 5 ~ Infections

Chapter 5 ~ Infections: Special Section 1 of 6 Chapter 5 ~ Infections Please refer to The Hillingdon Hospitals NHS Trust Antibiotic Guidelines, Policy number 233, and Surgical Prophylaxis Policy, Policy

MYELODYSPLASTIC AND MYELOPROLIFERATIVE

MYELODYSPLASTIC AND MYELOPROLIFERATIVE DISORDERS Pediatric Hemato-Oncology Division Medical Faculty University of Sumatera Utara 1 MYELODYSPLASIA SYNDROME A group of disorder defect in hematopoetic cell

Remicade (infliximab) DRUG.00002

Applicability/Effective Date *- Florida Healthy Kids Remicade (infliximab) DRUG.00002 Override(s) Prior Authorization Step Therapy Medications Remicade (infliximab) Approval Duration 1 year Comment Intravenous

The Italian AIDS Epidemic Supports The Chemical AIDS Theory. Daniele Mandrioli

The Italian AIDS Epidemic Supports The Chemical AIDS Theory Daniele Mandrioli EPIDEMIOLOGY France Population: 65.073.482 AIDS Incidence: 16/million Germany Population: 82.438.000 AIDS Incidence: 4/million

Rajasthan Medical Services Corporation Limited, Jaipur

Rajasthan Medical Services Corporation Limited, Jaipur List of Drugs- Purchase order placed to successful Bidders Tendered on 05/07/2011 S.No. Name of Drug 1 Atropine Sulphate Injection 0.6 mg /ml (SC/IM/IV

ATC/DDD classification

ATC/DDD classification The Anatomical Therapeutic Chemical (ATC) classification system and the Defined Daily Dose (DDD) as a measuring unit are tools for exchanging and comparing data on drug use at international,

AETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Colony Stimulating Factor (CSF)

AETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Colony Stimulating Factor (CSF) Colony Stimulating Factor (CSF) Neupogen (filgrastim; G-CSF), Neulasta (peg-filgrastim; G-CSF); Neulasa

Pediatric Toxic Hypoglycemia. Sara Kazim, MD, FRCP (EM) Clinical Pharmacology and Medical Toxicology Fellowship IEMC May Antalya

Pediatric Toxic Hypoglycemia Sara Kazim, MD, FRCP (EM) Clinical Pharmacology and Medical Toxicology Fellowship IEMC May 2016 - Antalya Conflicts of Interests... None Learning Needs... By the end of this

R-IDARAM. Dexamethasone is administered as an IV infusion in 100mL sodium chloride 0.9% over 30 minutes.

R-IDARAM Indication Secondary CNS lymphoma ICD-10 codes Codes with a prefix C85 Regimen details Day Drug Dose Route 1 Rituximab 375mg/m 2 IV infusion 1 Methotrexate 12.5mg Intrathecal 1 Cytarabine 70mg

Prescribe appropriate immunizations for. Prescribe childhood immunization as per. Prescribe influenza vaccinations in high-risk

Supplemental Digital Appendix 1 46 Health Care Problems and the Corresponding 59 Practice Indicators Expected of All Physicians Entering or in Practice Infectious and parasitic diseases Avoidable complications/death

Immunocompetence The immune system responds appropriately to a foreign stimulus

Functions of the immune system Protect the body s internal environment against invading organisms Maintain homeostasis by removing damaged cells from the circulation Serve as a surveillance network for

Chapter 4 Section 9.1

Surgery Chapter 4 Section 9.1 Issue Date: August 26, 1985 Authority: 32 CFR 199.4(c)(2) and (c)(3) 1.0 CPT 1 PROCEDURE CODES 33010-33130, 33140, 33141, 33200-37186, 37195-37785, 92950-93272, 93303-93581,

Annual Flash Report (unaudited) Fiscal Year ended March 31, 2017

Annual Flash Report (unaudited) Fiscal Year ended March 31, 2017 Supplemental nation Status of Development Pipeline as of May 8, 2017. Main Status of Development Pipelines (Oncology) 1. Development Status

Infliximab/Infliximab-dyyb DRUG.00002

Infliximab/Infliximab-dyyb DRUG.00002 Override(s) Prior Authorization Step Therapy Medications Remicade (infliximab) Inflectra (inflectra-dyyb) Approval Duration 1 year Comment Intravenous administration

Circle Yes or Y N. [Note: requests without this information will not be accepted.] [If no, then no further questions.

10/01/2016 Prior Authorization Aetna Better Health of West Virginia COLO STIMULATIG FACTORS (WV88) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,

NCCP Chemotherapy Regimen

INDICATIONS FOR USE: SUNitinib 50mg Therapy INDICATION ICD10 Regimen Code *Reimbursement Status Treatment of unresectable and/or metastatic malignant gastrointestinal C26 00325a CDS stromal tumour (GIST)

Immunosuppressants. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

Immunosuppressants Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Immunosuppressive Agents Very useful in minimizing the occurrence of exaggerated or inappropriate

1 17 ACITRETIN 10MG CAP 20, ,000 14,000 4, ACITRETIN 25MG CAP 50, ,000 35,000 10,000

ردیف کد ژنریک نام ژنریک مبلغ پوشش وزارت بهداشت مبلغ پوشش بیمه مبلغ پرداخت بیمار درصد پرداخت بیمار قیمت اعالمی وزارت بهداشت نام تجاری 1 17 ACITRETIN 10MG CAP 20,000 10.0 2,000 14,000 4,000 2 18 ACITRETIN

January 2018 Pharmacy & Therapeutics Committee Decisions

UCare s Pharmacy and Therapeutics Committee (P&T) is a group of physicians and pharmacists that meet throughout the year to make changes to the UCare formulary (approved drug list). These changes are reviewed

NCCP Chemotherapy Regimen. Tretinoin (ATRA)/Idarubicin (PETHEMA AIDA) Induction Therapy

Tretinoin INDICATIONS FOR USE: Regimen Code 00366a *Reimbursement Indicator INDICATION ICD10 Treatment of patients with newly diagnosed Acute C92 Promyelocytic Leukaemia (APL) *If a reimbursement indicator

UNC INFLAMMATORY BOWEL DISEASE DRUG PROTOCOL VEDOLIZUMAB (ENTYVIO)

UNC INFLAMMATORY BOWEL DISEASE DRUG PROTOCOL VEDOLIZUMAB (ENTYVIO) TREATMENT PROTOCOL: Vedolizumab is a humanized immunoglobulin G1 monoclonal antibody that targets 41 integrin and blocks its interaction

NCCP Chemotherapy Regimen. DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH)

DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH) Note: There is an option for Dose Dense DOXOrubicin, cyclophosphamide PACLitaxel

What is a hematological malignancy? Hematology and Hematologic Malignancies. Etiology of hematological malignancies. Leukemias

Hematology and Hematologic Malignancies Cancer of the formed elements of the blood What is a hematological malignancy? A hematologic malignancy is a malignancy (or cancer) of any of the formed elements

Viral Infections. 1. Prophylaxis management of patient exposed to Chickenpox:

This document covers: 1. Chickenpox post exposure prophylaxis 2. Chickenpox treatment in immunosuppressed/on treatment patients 3. Management of immunosuppressed exposed to Measles All children with suspected

Cardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE. Drug: MYCOPHENOLATE MOFETIL/SODIUM Protocol number: CV 15

Cardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE Drug: MYCOPHENOLATE MOFETIL/SODIUM Protocol number: CV 15 Indication: RENAL, PANCREAS OR COMBINED RENAL PANCREAS TRANSPLANTATION

Gazyva. Gazyva (obinutuzumab) Description

Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.29 Subject: Gazyva Page: 1 of 7 Last Review Date: September 15, 2016 Gazyva Description Gazyva (obinutuzumab)

The chemical name of acyclovir, USP is 2-amino-1,9-dihydro-9-[(2-hydroxyethoxy)methyl]-6Hpurin-6-one; it has the following structural formula:

Acyclovir Ointment, USP 5% DESCRIPTION Acyclovir, USP, is a synthetic nucleoside analogue active against herpes viruses. Acyclovir ointment, USP 5% is a formulation for topical administration. Each gram

NCCP Chemotherapy Regimen. Tretinoin (ATRA)/IDArubicin (PETHEMA AIDA) Induction Therapy: High Risk

Tretinoin : High Risk INDICATIONS FOR USE: INDICATION ICD10 Regimen Code *Reimbursement Status Treatment of patients with newly diagnosed high risk Acute Promyelocytic Leukaemia (APL) C92 00366a Hospital

OrphaNews Europe: How are orphan medicinal products categorised in Turkey?

Spotlight on...medicinal products for rare diseases in Turkey Interview In November 2008, Turkish pharmacist Pelin Kilic joined the team of Orphanet France in order to pursue her PhD studies in gene technology,

Antimycobacterial drugs. Dr.Naza M.Ali lec Dec 2018

Antimycobacterial drugs Dr.Naza M.Ali lec 14-15 6 Dec 2018 About one-third of the world s population is infected with M. tuberculosis With 30 million people having active disease. Worldwide, 9 million

NCCP Chemotherapy Regimen. Bevacizumab 5mg/kg and FOLFIRI Therapy 14 days

Bevacizumab 5mg/kg and FOLFIRI Therapy 14 days INDICATIONS FOR USE: Regimen Code 00449a INDICATION ICD10 Treatment of adult patients with metastatic carcinoma of the colon or C18 rectum. C19 C20 *If the

DERBY-BURTON LOCAL CANCER NETWORK FILENAME R-IVE.DOC CONTROLLED DOC NO: HCCPG B53 CSIS Regimen Name: R-IVE. R-IVE Regimen

R-IVE Regimen Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient Indication Relapsed/ refractory

5-Fluorouracil, epirubicin 100 and Cyclophosphamide (FEC 100) Therapy

5-Fluorouracil, epirubicin 100 and Cyclophosphamide (FEC 100) Therapy INDICATIONS FOR USE: Regimen INDICATION ICD10 Code Neoadjuvant treatment for breast carcinoma C50 00265a Adjuvant treatment for breast

To provide guidance on prevention and control of illness caused by varicella-zoster virus (VZV).

Effective Date: 04/18 Replaces: 0 4 / 1 3 / 1 7 Page 1 of 4 POLICY: To provide guidance on prevention and control of illness caused by varicella-zoster virus (VZV). DEFINITIONS Two syndromes occur from

Evolving therapies for posterior uveitis. Infliximab (Remicade) Infliximab: pharmacology. FDA-approved monoclonal antibody therapy Target

Evolving therapies for posterior uveitis Sam Dahr, M.D. September 17, 2005 Midwest Ophthalmology Conference Infliximab (Remicade) FDA approved for Crohn s disease, rheumatoid arthritis, and psoriatic arthritis

Liver failure &portal hypertension

Liver failure &portal hypertension Objectives: by the end of this lecture each student should be able to : Diagnose liver failure (acute or chronic) List the causes of acute liver failure Diagnose and

Legal aspects in accidents and neglect.

Al-Al Bayt University Princess Salma Faculty of Nursing Adult Health nursing Course Title :Child Health Nursing Course Number :1001341 Credit Hours :3 Pre requisite :1001222 Placement : Instructor:,, Course

Antiallergics and drugs used in anaphylaxis

Antiallergics and drugs used in anaphylaxis Antiallergics and drugs used in anaphylaxis The H 1 -receptor antagonists are generally referred to as antihistamines. They inhibit the wheal, pruritus, sneezing

Crohn's disease CAUSES COURSE OF CROHN'S DISEASE TREATMENT. Sulfasalazine

Crohn's disease Crohn's disease is an inflammatory condition of the digestive tract that affects children and adults. Common features of Crohn's disease include mouth sores, diarrhea, abdominal pain, weight

PVACE-BOP (Hodgkin s Lymphoma)

DRUG ADMINISTRATION SCHEDULE Day Drug Dose Route Diluent Rate 1 Ondansetron 8mg IV / Oral vinblastine 6mg/m 2 (Max: 10mg) IV Infusion Etoposide 100mg/m 2 IV infusion Patients over 65 years by 15 min infusion

Circle Yes or No Y N. (Note: requests without this information will not be accepted.) [If no, then no further questions.]

04/25/2016 Prior Authorization AETA BETTER HEALTH OF LA MEDICAID Colony Stimulating Factors (LA88) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,

2. Is therapy prescribed by, or in consultation with, a hematologist and/or oncologist?

Pharmacy Prior Authorization AETA BETTER HEALTH EW JERSE (MEDICAID) Colony Stimulating Factors (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review

VI.2 Elements for a public summary

VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Leukaemia is a cancer that starts in the blood-forming cells of the bone marrow. Chronic lymphocytic leukaemia (CLL) is a type

InterQual Level of Care 2018 Index

InterQual Level of Care 2018 Index Long-Term Acute Care (LTAC) Criteria The Index is an alphabetical listing of conditions and/or diagnoses designed to guide the user to the criteria subset where a specific

AETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Colony Stimulating Factor (CSF)

AETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Colony Stimulating Factor (CSF) Colony Stimulating Factor (CSF) Neupogen (filgrastim; G-CSF), Neulasta (peg-filgrastim; G-CSF); Neulasa

HEALTH SERVICES POLICY & PROCEDURE MANUAL

PAGE 1 of 6 PURPOSE To establish basic understanding of indications and contraindications for transplantation of various organs. POLICY The N.C. Department of Correction, Division of Prisons, Health Services

TRANSPARENCY COMMITTEE OPINION. 27 January 2010

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 27 January 2010 TORISEL 25 mg/ml, concentrate for solution and diluent for solution for infusion Box containing 1

An Overview of Blood and Marrow Transplantation

An Overview of Blood and Marrow Transplantation October 24, 2009 Stephen Couban Department of Medicine Dalhousie University Objectives What are the types of blood and marrow transplantation? Who may benefit

See Important Reminder at the end of this policy for important regulatory and legal information.

Clinical Policy: (Rayos) Reference Number: CP.CPA.273 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important

STEPHEN P. NONN OFFICE OF THE CORONER MADISON COUNTY, ILLINOIS 157 MAIN STREET SUITE 354 EDWARDSVILLE, IL

MAIN OFFICE: (618) 692-7478 MORGUE: (618) 296-4525 FAX: (618) 692-6042 FAX: (618) 692-9304 STEPHEN P. NONN OFFICE OF THE CORONER MADISON COUNTY, ILLINOIS 157 MAIN STREET SUITE 354 EDWARDSVILLE, IL. 62025-1962

NCCP Chemotherapy Regimen. Obinutuzumab and Chlorambucil Therapy

INDICATIONS FOR USE: Obinutuzumab INDICATION ICD10 Regimen Code *Reimbursement Indicator Treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) and with comorbidities

Parenteral Products. By: Howida Kamal, Ph.D

Parenteral Products By: Howida Kamal, Ph.D Dosage forms Route of administration Enteral INTO Parenteral ONTO Topical Dosage forms Physical form Solid Liquid Semi-solid Powder Granules Tablets Capsules

CANNABIS AND CANNABINOIDS: 2017 REPORT, U.S. NATIONAL ACADEMIES OF SCIENCES, ENGINEERING AND MEDICINE

1 CANNABIS AND CANNABINOIDS: 2017 REPORT, U.S. NATIONAL ACADEMIES OF SCIENCES, ENGINEERING AND MEDICINE The Health Effects of Cannabis and Cannabinoids. The Current State of Evidence and Recommendations

ICD-10-CM. Test Your Knowledge Chapter 5. Using your ICD-10-CM codebook, code the following:

ICD-10-CM Test Your Knowledge Chapter 5 Using your ICD-10-CM codebook, code the following: 1) Tuberculoma of meninges 2) Episcleritis tuberculosis 3) Late effects of respiratory tuberculosis 4) Tuberculosis

RITUXAN (rituximab and hyaluronidase human)

Drug Prior Authorization Guideline RITUXIMAB products J9310 RITUXAN (rituximab and hyaluronidase human) PA9847 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria

NCCP Chemotherapy Regimen

Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day and Trastuzumab Therapy (DD AC-TH) Note: There is an option for Dose Dense DOXOrubicin, cyclophosphamide

Ontario s Referral and Listing Criteria for Adult Pancreas-After- Kidney Transplantation

Ontario s Referral and Listing Criteria for Adult Pancreas-After- Kidney Transplantation Version 2.0 Trillium Gift of Life Network Adult Pancreas-After-Kidney Transplantation Referral & Listing Criteria

INFLAMMATORY DISEASES PART I. Immunopathology Part I

INFLAMMATORY DISEASES PART I Immunopathology Part I Nonspecific & T Cell Mediated Mucosal Inflammatory Lesions Nonspecific and Idiopathic Mucositis Hypersensitivity and Autoimmune T cell mediated Immunoglobulin

Cardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE. Drug: AZATHIOPRINE Protocol number: CV 04

Cardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE Drug: AZATHIOPRINE Protocol number: CV 04 Indication: RENAL, PANCREAS OR COMBINED RENAL PANCREAS TRANSPLANTATION LIVER

Inflectra (infliximab-dyyb), Remicade (infliximab), Renflexis (infliximab-abda) DRUG CG-DRUG-64

Inflectra (infliximab-dyyb), Remicade (infliximab), Renflexis (infliximab-abda) DRUG.00002 CG-DRUG-64 Override(s) Prior Authorization *Washington Medicaid See State Specific Mandates Medications Inflectra

R-BAC-500 (Rituximab, Bendamustine, Cytarabine) for Mantle Cell Lymphoma

R-BAC-500 (Rituximab, Bendamustine, Cytarabine) for Mantle Cell Lymphoma Not routinely commissioned, each case requires prior documented approval before offering & commencing therapy from NHS England Cancer

Neosynephrine. Name of the Medicine

Name of the Medicine Neosynephrine Phenylephrine hydrochloride 1% injection Neosynephrine Presentation Neosynephrine is a clear, colourless, aqueous solution, free from visible particulates, in sterile

NCCP Chemotherapy Regimen. Obinutuzumab Maintenance Therapy following O-Bendamustine therapy

Obinutuzumab following O-Bendamustine therapy INDICATIONS FOR USE: INDICATION Obinutuzumab maintenance therapy is indicated in patients with follicular lymphoma (FL) who have responded to induction treatment

Fungal infection in the immunocompromised patient. Dr Kirsty Dodgson

Fungal infection in the immunocompromised patient Dr Kirsty Dodgson Aims Discuss different types of fungi Overview of types of clinical infections Clinical Manifestations Fungus Includes Moulds Aspergillus

Neupogen (Filgrastim)/Neulasta (Pegfilgrastim)

Policy Number Reimbursement Policy NEU12182013RP Approved By UnitedHealthcare Medicare Reimbursement Policy Committee Current Approval Date 12/18/2013 IMPORTANT NOTE ABOUT THIS REIMBURSEMENT POLICY This

NCCP Chemotherapy Protocol. Ponatinib Therapy

INDICATIONS FOR USE: INDICATION Treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant

Hypertensives Emergency and Urgency

Hypertensives Emergency and Urgency Budi Yuli Setianto Cardiology Divisision Department of Internal Medicine Faculty of Medicine UGM Sardjito Hospital Yogyakarta Background USA: Hypertension is 30% of

CURRENT WORK PLAN New monographs for inclusion in The International Pharmacopoeia and revision of related monographs

page 1 CURRENT WORK PLAN New monographs for inclusion in The International Pharmacopoeia and revision of related monographs 2011 The following categories are included in this work programme: 1. Medicines

R-ICE Regimen- Rituximab, Etoposide, Ifosfamide (with MESNA), Carboplatin (+ Depocyte if CNS involvement)

R-ICE Regimen- Rituximab, Etoposide, Ifosfamide (with MESNA), Carboplatin (+ Depocyte if CNS involvement) Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case

H&HD ANTINEOPLASTIC DRUG CARD ASSEMBLY INSTRUCTIONS

H&HD ANTINEOPLASTIC DRUG CARD ASSEMBLY INSTRUCTIONS Each of you should have 37 new cards: 7 orange cards for antimetabolites 11 white cards for miscellaneous drugs (2 DNA synthesis inhibitors, 1 enzyme,

ANTI COLD / ANTI ALLERGIC / ANTI-ASTHMATICS GIT PRODUCTS

SR. NO 1 ANTI COLD / ANTI ALLERGIC / ANTI-ASTHMATICS Paracetamol 500 mg, Phenylephrine HCL 5 mg With Chlorpheniramine Maleate 2 mg & Caffeine 30 mg Tablets 2 Salbutamol Tablets BP 2 mg 3 Salbutamol Tablets

OMCJH.CHEM.COLL.INF.1001 Therapeutic Drug Monitoring Guidelines

OMCJH.CHEM.COLL.INF.1001 Copy of version 1.0 (approved and current) Last Approval or Periodic Review Completed 10/5/2017 Next Periodic Review Needed On or Before 10/5/2019 Effective Date 10/5/2017 Controlled

NCCP Chemotherapy Protocol. CHOEP Therapy 21 days. Treatment of T-cell Non-Hodgkins Lymphoma C a

CHOEP Therapy 21 days INDICATIONS FOR USE: INDICATION ICD10 Protocol Code Treatment of T-cell Non-Hodgkins Lymphoma C85 00396a ELIGIBILTY: Indication as above Age < 60 years Adequate haematological, renal

Chapter 4 Section 9.1

Surgery Chapter 4 Section 9.1 Issue Date: August 26, 1985 Authority: 32 CFR 199.4(c)(2) and (c)(3) 1.0 CPT 1 PROCEDURE CODES 33010-33130, 33140, 33141, 33361-33369, 33200-37186, 37195-37785, 92950-93272,

Drugs That Require Prior Authorization (PA) Before Being Approved for Coverage

Drugs That Require Prior Authorization (PA) Before Being Approved for Coverage You will need authorization by your UA Medicare Part D Prescription Drug Plan before filling prescriptions for the drugs shown

For peripheral blood stem cell (PBSC) mobilization prior to and during leukapheresis in cancer patients preparing to undergo bone marrow ablation

Last Review: 4/2010 NON-FORMULARY Clinical Guideline Neupogen (filgrastim; G-CSF), Neulasta (peg-filgrastim; G-CSF), Neumega (oprelvekin; rh-il-11), Leukine (sargramostim; GM-CSF) Indications Neupogen

COURSE OUTLINE Pathophysiology

Butler Community College Health, Education, and Public Services Division Denise LaKous Revised Spring 2014 Implemented Fall 2015 Textbook Update Fall 2015 COURSE OUTLINE Pathophysiology Course Description

Manufacturing and Marketing permission issued from SND Division from to

Manufacturing and Marketing permission issued from SND Division from 01.01.2018 to 28.09.2018. S.No Drug Name Composition Indication Date of Approval As a component of multi agent Pegaspargase Each vial

Product Visual Guide

Product Visual Guide Teamwork A team with an unflinching faith in one another is one of our core strength. Excellence Achieving excellence is not the end result, we begin with excelling in any endeavor.

Gazyva (obinutuzumab)

STRENGTH DOSAGE FORM ROUTE GPID 1000mg/40mL Vial Intravenous 35532 MANUFACTURER Genentech, Inc. INDICATION(S) Gazyva (obinutuzumab) is a CD20- directed cytolytic antibody and is indicated, in combination

Bevacizumab 10mg/kg 14 days

INDICATIONS FOR USE: Bevacizumab 10mg/kg 14 days Regimen Code 00212a *Reimbursement status Hospital INDICATION ICD10 In combination with fluoropyrimidine-based chemotherapy C18 for treatment of adult patients

Product Catalog. Pediatric Learning Solutions. Listing of all current products (as of May, 2013) offered by Children's Hospital Association.

Product Catalog Pediatric Learning Solutions Listing of all current products (as of May, 2013) offered by Children's Hospital Association. Acquired Heart Disease in Children WBT Acute Respiratory Distress

Risk Evaluation and Mitigation Strategy (REMS): Cytokine release syndrome and neurological toxicities

Risk Evaluation and Mitigation Strategy (REMS): Cytokine release syndrome and neurological toxicities A REMS is a program required by the FDA to manage known or potential serious risks associated with

Clinical Toxicology Toxicity of Digitalis Glycosides 5 th Year (Lab 3)

Clinical Toxicology Toxicity of Digitalis Glycosides 5 th Year (Lab 3) Lecturer: Rua Abbas Al-Hamdy Department of Pharmacology & Toxicology University of Al-Mustansiriyah 2017-2018 Introduction: Digitalis